Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cells within cancer that contribute to cancer initiation and progression. Cancer-associated fibroblasts (CAFs) are stromal fibroblasts surrounding tumor cells, and they have important roles in tumor growth and tumor progression. It has been suggested that stromal fibroblasts and CSCs/CICs might mutually cooperate to enhance their growth and tumorigenic capacity. In this study, we investigated the effects of fibroblasts on tumor-initiating capacity and stem-like properties of ovarian CSCs/CICs. CSCs/ CICs were isolated from the ovarian carcinoma cell line HTBoA as aldehyde dehydrogenase 1 high (ALDH1 high ) population by the ALDEFLUOR assay. Histological examination of tumor tissues derived from ALDH1
Tumors are composed of morphologically and phenotypically heterogeneous cells that are derived from a small subpopulation of pluripotent stem-like cancer cells (cancer stem cell hypothesis). [1] [2] [3] Cancer stem-like cells (CSCs) are also named as cancer-initiating cells (CICs) since they possess high tumorigenic capacity in vivo. With recent progress in this research field, CSCs/CICs have been isolated by several methods. 4 CSCs/CICs are now defined as a small population of cancer cells that have (1) high tumor-initiating capacity, (2) self-renewal capacity and (3) differentiation potential. Since CSCs/CICs are resistant to conventional cancer therapies including chemotherapy, radiotherapy and some molecular targeting therapies, they are thought to be responsible for disease recurrence and distant metastasis. 5 CSCs/CICs have phenotypic properties similar to those of normal stem cells; however, the molecular mechanisms underlying their high tumorigenic capacity, a hallmark of CSCs/CICs, are still elusive.
Tumor microenvironments have important roles in cancer progression. 6 They are composed of cancer cells and surrounding stromal elements, such as blood vessels, inflammatory cells and fibroblasts, which are termed as cancer-associated fibroblasts (CAFs). 7 CAFs are activated fibroblasts that can be identified by immunohistochemical staining using anti-asmooth muscle actin (a-SMA). 8, 9 These fibroblasts are also known as reactive fibroblasts, peri-tumor fibroblasts and myofibroblasts. 10 CAFs are observed in various types of malignancies including gastric cancer, ovarian cancer and breast cancer. In many cases, tumors with abundant CAFs have a poorer prognosis than those of tumors with less CAFs, since CAFs have significant roles in the tumor microenvironment for promotion of cell growth and invasion. 11, 12 It has also been suggested that CSCs/CICs might preferentially interact with CAFs, which serve as a niche in the CSC/CIC microenvironment. 13 In this study, we show evidence that fibroblasts can induce expression of stemness-associated genes and fibroblast growth factor 4 (FGF4) in ovarian carcinoma CSCs/CICs, leading enhancement of tumor-initiating capacity. Our study highlights the significance of FGF4-FGFR2 signaling induced by the interaction between fibroblasts and CSCs/CICs in the tumor microenvironment.
MATERIALS AND METHODS Cell Culture
The experiments were conducted with the approval of the Sapporo Medical University Study Review Board. The human ovarian carcinoma cell line HTBoA was previously established from an ovarian anaplastic carcinoma. 14 Human primary skin fibroblasts N25-5 and N30-3 were prepared from normal skin tissues of two Japanese patients who underwent plastic surgery after obtaining informed consent, in compliance with the ethical guidelines of Sapporo Medical University School of Medicine. All cells were maintained in Dulbecco's modified Eagle's medium (DMEM; SigmaAldrich, St Louis, MO, USA) supplemented with 10% FBS in a 5% CO 2 incubator at 37 1C.
ALDEFLUOR Assay
An ALDEFLUOR assay kit was purchased from Stem Cell Technologies (Vancouver, BC, Canada) and used according to the manufacturer's recommendations. Briefly, 10 6 cells were suspended in 1 ml assay buffer containing 1.5 mM of an ALDH1 substrate, BODIPY s -aminoacetaldehyde (BAAA), and incubated for 50 min at 37 1C. An inhibitor of ALDH1, diethylamino-benzaldehyde (DEAB), at a 10-fold molar excess was used as a negative control. Flow cytometry and cell sorting were performed using a FACS Aria II cell sorter (BD Biosciences, Bedford, MA, USA).
In Vivo Tumor Formation Assay
The experiments were conducted with the approval of the Sapporo Medical University Study Review Board. ALDH1 high cells and ALDH1 low cells isolated from HTBoA cells were resuspended at 10 2 -10 4 cells in 50 ml of PBS and mixed with 50 ml of matrigel (BD Biosciences). The cell-matrigel mixture suspension was subcutaneously injected in the dorsum of 6-week-old non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice (NOD.CB17-Prdkcscid/J, Charles River Laboratory, Yokohama, Japan) under anesthesia. , Complete Serum-Free Medium after 2 days of culture. The supernatant was added to the sphere culture medium to a final concentration of 50%.
Immunohistochemical Staining
Human leukocyte antigen (HLA) immunostaining was performed using mouse monoclonal anti-HLA class I antibody (clone: EMR8-5) as described previously. 15 The monoclonal antibody was used at 1 mg/ml. a-SMA staining, FGF4 staining and FGFR2 staining were done using rabbit polyclonal antialpha smooth muscle actin antibody (Abcam, Cambridge, MA, USA), anti-FGF4 antibody (Abcam) and anti-FGFR2 antibody (Abcam). The antibodies were used at 1 mg/ml.
RT-PCR Analysis
Total RNA was reverse-transcribed using Superscript II reverse transferase enzyme (Life Technologies, Grand Island, NY, USA). PCR was performed using Taq polymerase (Qiagen, Valencia, CA, USA). The thermal cycling conditions were 94 1C for 2 min followed by 35 Quantitative Real-Time PCR Analysis (qPCR) Quantitative real-time PCR was performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. ALDH1A1 (Hs00946916_m1), SOX2 (Hs01053049_s1), POU5F1 (Hs00999632_g1), NANOG (Hs04260366_g1), CD44 (Hs01075861_m1), DNAJB8 (Hs00542087_s1) primers and probes were designed by the manufacturer (TaqMan Gene expression assays; Applied Biosystems). Thermal cycling was performed using 40 cycles of 95 1C for 15 s followed by 60 1C for 1 min. Each experiment was done in triplicate, and normalized to the GAPDH gene as an internal control.
Gene Knockdown of FGFR2 with Small-Interfering RNA FGFR2 small-interfering RNAs (siRNAs) (SiHK0771) (Sigma, Tokyo, Japan) were used to knockdown FGFR2 mRNA. Transfection of siRNA duplexes was performed with Lipofectamine RNAimax (Life Technologies) according to the manufacturer's manual. Gene knockdown was confirmed by RT-PCR.
Statistical Analysis
Statistical analysis, data fitting and graphics were performed by the SPSS software package ver.19 (SPSS, Chicago, IL, USA). Data were shown as the mean ± s.d. of at least three independent experiments and Student's t-test was used to assess the statistical significant difference (Po0.05). Overall survival (OS), which was defined as interval from the date of first diagnosis to the date of death of disease progression, and progression-free survival (PFS), interval from the date of first diagnosis to the date of disease progression, were estimated using Kaplan-Meier method and compared with the log-rank test. The relevance with FGF4 expression was analyzed by Pearson's w-square tests. Correlation coefficient between 4 In our previous study, we found that CSCs/CICs of ovarian carcinoma MCAS cells were enriched in an aldehyde dehydrogenase high activity population (ALDH1 high ) by the ALDEFLUOR assay as well as in a side population by the Hoechst33342 assay. 16 18 We therefore examined whether fibroblasts can affect the tumorigenic capacity of CSCs/CICs of ovarian cancer cells. Ten thousand ALDH1 high cells with or without a mixture of normal skin fibroblasts (N25-5) were inoculated into NOD/SCID mice (Figure 2a) . Fibroblastmixed ALDH1 high cells showed a higher tumor incidence (5 of 5) and formed significantly larger tumors than did ALDH1 high cells without a mixture of fibroblasts ( Figure 2b ; Table 2 ). Neither ALDH1 low only cells nor fibroblast-mixed ALDH1 low cells exhibited tumor formation in five mice ( Table 2 ). Histological examination revealed that fibroblastmixed ALDH1
high tumor tissues contained abundant fibrous stroma, whereas ALDH1 high only tumor tissues contained few stroma (Figures 2c and d) . The stromal fibroblasts were negative for HLA class I and positive for a-SMA by immunohistochemical examination, indicating that they were CAFs derived from recipient mouse (Figure 2d ). Similar results were confirmed by the experiments using another fibroblasts (N30-3) (Supplementary Figure 1) . Next, we examined in vitro sphere formation capacity of ALDH1 high and ALDH1 low cells in the presence or absence of fibroblasts ( Figure 3 ). ALDH1 high cells exhibited significantly higher sphere formation capacity in the presence of fibroblasts than those without fibroblasts or ALDH1 low cells. Mixture of fibroblasts could not enhance the sphere formation capacity of ALDH1 low cells. SMA-positive fibroblasts were observed in peripheral region of the spheres derived from HTBoA mixed with fibroblasts. These data indicate that normal fibroblasts promote the tumor-initiating capacity and CAF induction capacity of CSCs/CICs, but not those of non-CSCs/CICs.
Cancer Stemness Genes were Upregulated in a Fibroblast-Mixed ALDH1
high Tumor Tumor-initiating capacity, as determined by an in vivo tumor formation assay and an in vitro sphere formation assay, is a hallmark of CSCs/CICs and is closely associated with the expression of cancer stemness genes such as SOX2, POU5F1 and NANOG. DNAJB8 is a newly identified CSC-related gene that controls tumor-initiating ability in renal CSCs. 19 Table 1 Tumor-initiating capacity of HTBoA ovarian cancer cells Cancer-associated fibroblasts and cancer stem cells K Yasuda et al Therefore, expression levels of these cancer stemness genes were examined by quantitative real-time PCR. CSC/CIC-related genes were upregulated in fibroblast-mixed ALDH1 high tumors (Figure 4a ). Protein levels of SOX2 and ALDH1 were also increased in fibroblast-mixed ALDH1 high tumor tissues as detected by immunohistochemical staining (Figure 4b ).
FGF4 Gene Expression was Induced in ALDH1 high Cells after Mixing with Fibroblasts
To determine the differences between gene expression in CSC/CIC-derived tumors with CAFs (fibroblast-mixed ALDH1 high tumors) and those without CAFs (ALDH1 high only tumors), comparative gene expression analysis was performed by RT-PCR. Previous report presented that FGF family might be involved with stromal induction of cancer. 20 The expression levels of four FGF family genes (FGF3, FGF4, FGF5 and FGF6) that are related to oncogenesis were addressed, in tumor samples derived from fibroblast-mixed ALDH1 high cells, and only ALDH1 high cells (Figure 5a ). Fibroblast line cells were also used as a control. FGF3, FGF5 and FGF6 were undetectable in tumors derived from fibroblast-mixed ALDH1 high cells, and only ALDH1 high cells. Whereas, FGF4 was detected in tumor derived from fibroblast-mixed ALDH1 high cells; however, FGF4 was undetectable in tumor derived from only ALDH1 high cells. The data suggested that FGF4 was a candidate for stromal induction. FGF4 is not only a growth factor for fibroblasts but also an oncogenic growth factor that has potential to transform mice embryonal fibroblasts. 21 Therefore, we further analyzed the expression levels of FGF4 and its related genes by RT-PCR. As shown in Figure 5b Figure 1) . The expression levels of FGF4 receptor (FGFR2), TGF-b signaling molecules (TGFB1 and SMAD2) and inflammatory signaling molecules (IL-1B and STAT3) were also higher in fibroblast-mixed
ALDH1
high tumors than in ALDH1 high only tumors. FGF4 gene expression level was also increased after co-culture of ALDH1 high cells with fibroblasts, although FGFR2 expression level was not changed (Figure 5c ). In contrast to ALDH1 high cells, ALDH1 low cells barely expressed FGFR2, and FGF4 gene expression was not detected even after co-culture with fibroblasts ( Figure 5c ). In Figure 5d , positivity to anti-FGF4 and anti-FGFR2 antibody was extremely high in tumors derived from fibroblast-mixed ALDH1
high cells compared with that in tumors derived from ALDH1 high cells.
FGF4-FGFR2
Signaling has an Important Role in the Sphere-Forming Capacity of Fibroblast-Mixed ALDH1 high Cells To determine the significance of FGF4 gene expression in the mechanism of fibroblast-induced cancer stemness in ALDH1 high cells, we examined the sphere-forming capacity in the presence of recombinant human FGF4. FGF4 significantly enhanced the sphere-forming capacity of ALDH1 high cells but not that of ALDH1 low cells (Figure 6a ). These results are consistent with the findings that the FGF4 receptor is expressed on ALDH1 high cells but is expressed at a very low level on ALDH1 low cells (Figure 5c ). Next, we examined the effect of FGFR2 knockdown on the sphere-forming capacity of ALDH1 high cells in the presence or absence of fibroblasts. The sphere-forming capacity of ALDH1 high cells was dramatically suppressed by knockdown of FGFR2 even in the absence of fibroblasts (Figure 6b ). These results indicate that FGFR2 is crucial not only for the fibroblast-induced sphereforming capacity of CSCs/CICs but also for the basal sphereforming capacity in the absence of fibroblasts. FGFR2 is known to function as a receptor for several FGF family growth factors. Indeed, the sphere culture medium contained FGF2 (bFGF), for which FGFR2 acts as a receptor.
Soluble Factors Released from Fibroblasts can Promote the Sphere-Forming Capacity of ALDH1
high Cells To determine whether cell-to-cell contact is required for the promotion of sphere formation, we collected fibroblast culture supernatant and examined the activity. Normal human fibroblasts were cultured in CSC Certified TM , Complete Serum-Free Medium for 2 days. Then, the supernatant was added to the sphere culture. As shown in Figure 7 , fibroblast culture supernatant enhanced the sphere-forming capacity of ALDH1 high cells but not that of ALDH1 low cells. These results indicate that cell-to-cell contact between fibroblasts and CSCs/CICs is not required and that soluble factors released from fibroblasts have activity for enhancing the sphere formation capacity of CSCs/CICs of HTBoA cells.
High Expression Levels of FGF4 are Associated with Poor Prognosis
A total 122 of epithelial ovarian cancer tissues were immunohistochemically stained with anti-FGF4 antibody and counted the positivity of staining. We divided into three groups Tumor formation was evaluated at day 70 post inoculation.
Cancer-associated fibroblasts and cancer stem cells K Yasuda et al Cancer-associated fibroblasts and cancer stem cells K Yasuda et al Cancer-associated fibroblasts and cancer stem cells K Yasuda et al Cancer-associated fibroblasts and cancer stem cells K Yasuda et al (Table 3 ; Figure 8a ): Score 0 (FGF4 positivity; o5%), Score 1 (FGF4 positivity; 45%, o10%) and Score 2 (FGF4 positivity; 410%). The data were summarized in Table 3 . FGF4 score 0 is significantly less in serous adenocarcinoma cases, and FGF4 score 1 is significantly higher in serous adenocarcinoma cases (P ¼ 0.004). FGF4 score 0 is correlated with FIGO Stage I and score 2 is correlated with FIGO Stage IV (Po0.001). The high expression of ALDH1 was correlated with poorer prognosis in previous study. 16 The correlation of FGF4 expression and ALDH1 expression was analyzed. There Cancer-associated fibroblasts and cancer stem cells K Yasuda et al were weak but significant correlation between FGF4-positive rates and ALDH1-positive rates (r ¼ 0.234, P ¼ 0.009) (Supplementary Figure 3 ). In Figure 8b , log-rank test revealed that higher expression of FGF4 (Score 1 and Score 2) is associated with poorer prognosis with a significant difference than those of lower expression levels of FGF4 (P ¼ 0.004). Higher expression levels of FGF4 showed tendency with shorter PFS than those of lower expression levels of FGF4.
The Expression Level of FGF4 and the Ratio of CAFs Have Certain Correlation A total 122 of epithelial ovarian cancer tissues were also stained with a-SMA antibody and counted the positivity of staining as the ratio of CAFs (Figure 8c ). The ratio of CAF and FGF4 positivity rate were plotted and correlation coefficient was analyzed by CORREL function (Figure 8d ). Correlation coefficient is 0.56. The expression level of FGF4 and the ratio of CAFs are associated with significant correlation (Po0.01).
DISCUSSION
The cancer microenvironment has critical roles in cancer initiation, progression, invasion and metastasis, and CAF is a major component of the cancer microenvironment. 6 Actually, CAFs have roles in the adhesion and motility of tumor cells, and it is known that cancer cases with abundant CAFs have a poorer prognosis than that of cases with few CAFs. 9, 11 Importantly, recent studies have indicated that stem-like phenotypes are more interactive with the cancer microenvironment. Therefore, we examined the interaction between fibroblasts and CSCs/CICs. In the present study, we first demonstrated that highly tumorigenic CSCs/CICs could be isolated in an ALDH1 high population from HTBoA ovarian carcinoma cells. Previous studies showed successful isolation of ovarian CSCs/CICs by the ALDEFLUOR assay. 22 Therefore, the ALDEFLUOR assay is a promising approach to isolate ovarian CSCs/CICs. We next examined the action of fibroblasts on the tumor initiation capacity of CSCs/CICs and the histology of tumors. ALDH1 high tumors recruited prominent CAFs that were derived from recipient mice when inoculated with normal fibroblasts. Furthermore, a mixture with fibroblasts enhanced the expression of stem cell markers, in vivo tumor-initiating capacity and sphere-forming capacity of ALDH high cells, indicating that cancer stem-like properties were upregulated by the action of fibroblasts.
RT-PCR analysis revealed that the FGF4 gene was expressed in fibroblast-mixed ALDH1 high cells and tumor tissues. FGF4 is known to have a key role in maintaining the self-renewal potential of normal stem cells such as trophoblastic stem cells. 23 Moreover, the role for FGF4 of tumor invasion have also speculated. 23 We showed that FGF4 could enhance the sphere-forming capacity of ALDH1 high cells, indicating that FGF4 might be one of the growth factors mediating the stemness-promoting action of fibroblasts on CSCs/CICs. FGF4 was initially isolated as an oncogene that could transform NIH3T3 cells. 20 FGF4 gene amplification has been reported in various human cancers. [24] [25] [26] [27] The FGF4 gene is expressed from the early stage of embryonic development in fetal life and has essential roles in cell differentiation, morphogenesis and proliferation of a variety of organizations. 28 In human adult organs, FGF4 is highly expressed in the testis. Thus, FGF4 is one of key growth factors controlling proliferation and differentiation of normal stem cells or progenitor cells as well as cancer cells. In this study, we observed high FGF4 protein expression was correlated with poorer prognosis of ovarian cancer cases. Higher FGF4 expression rates were correlated with advanced stage and serous adenocarcinoma cases. Serous adenocarcinoma has high invasive feature than other histological subtypes, and invasion into stroma enables cancer cells to contact with CAFs physically. 29 Thus, invasion into stroma might be first step to induce FGF4-positive CSCs/CICs.
In our study, knockdown of FGFR2, a receptor for FGF4 and other FGF family factors, almost completely inhibited sphere-forming capacity. 30 Therefore, it is thought that FGFR2 signaling has a crucial role in the maintenance of cancer stemness properties such as sphere formation and in vivo tumor initiation in ovarian cancer HTBoA cells. FGF4 production is induced in CSCs/CICs by stimulation of fibroblast-secreting factors and then FGF4 promotes tumor initiation through autocrine and paracrine mechanisms ( Figure 9 ). Interestingly, FGF4 gene expression is controlled by transcription factors POU5F1 (Oct3/4) and Sox2, which Figure 9 Working model of the role of FGF4-FGFR2 signaling in the interaction between CSCs/CICs and CAFs. Fibroblasts secrete unknown factors that stimulate FGF4 production in CSCs/CICs. FGF4 enhances the sphere-forming capacity and in vivo tumor initiation capacity by autocrine and paracrine mechanisms. FGF4 also recruits and activates CAFs.
Cancer-associated fibroblasts and cancer stem cells K Yasuda et al are well-known cancer stem cell markers. 31 The results of the present study are consistent with these mechanisms, since both stem cell markers were upregulated in a fibroblastmixed ALDH1 high tumor (Figure 4a ). It should be noted, however, that other FGFR2 ligands might also be produced in CSCs/CICs, since knockdown of FGF4 could partially but not completely abrogate the stemness-promoting action of fibroblasts.
Various growth factors and cytokines produced from fibroblasts, including TGF-b, 8, [32] [33] [34] have been reported to have important roles in the tumor microenvironment for promotion of the aggressiveness of cancer cells. Chao et al 13 reported that CD133 þ colon CSCs expressed high levels of CXCR4 and were highly reactive to SDF1, which is secreted from CAFs. Tsuyada et al 35 reported that cancer cell-secreting cytokines stimulated production of CCL2 in activated fibroblasts, which in turn activated Notch signaling and sphere-forming capacity in breast cancer stem cells. Thus, fibroblast-secreting factors have important roles in the maintenance of stem-like phenotypes and tumorigenicity of CSCs/CICs. It is important to identify the unknown fibroblast-secreting factors that induced FGF4 expression in ovarian CSCs/CICs in our study. Such factors and FGFR2 signaling might be potential targets for CSC/CIC-targeting therapy.
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